Foli Bio, a Columbia University spinout, is developing stool‑based RNA‑seq panels from exfoliated fecal RNA to predict drug response in inflammatory bowel disease and reduce reliance on endoscopy for disease monitoring. The startup’s initial product roadmap targets predictive biomarkers to personalize therapy selection and surveillance for IBD patients, with the goal of enabling noninvasive longitudinal assessment. The approach leverages advances in nucleic‑acid extraction from stool and bioinformatics to correlate mucosal biology with treatment outcomes. If validated in clinical cohorts, the panels could shift care pathways for IBD toward bloodless, home‑based monitoring and support drug‑response stratification in clinical trials and practice.